Freenome reported that an updated version of its SimpleScreen CRC blood test met primary and secondary endpoints in a clinical validation study, but stakeholders reacted as mixed. The study used blinded, previously unevaluated samples from the prospective registrational PREEMPT CRC cohort plus previously tested materials across more than 200 sites. Across 48,995 asymptomatic average-risk adults, Freenome reported overall sensitivity of 80.4% and 90% specificity. Sensitivity for advanced precancerous lesions was reported at 18.2% for APL detection and 41.9% for high-grade dysplasia lesions, with higher sensitivity reported for late-stage cancers. Compared with the prior version, overall sensitivity declined slightly, but sensitivity for precancerous lesions improved. Freenome also stated the updated assay would yield modest gains in life-years gained and cancer outcomes compared with the first version, while the company did not comment further to the report.